Oui, des problèmes d'anxiété et de dépression peuvent survenir en raison de l'image corporelle.
AnxiétéDépressionLipodystrophie
#4
Comment la lipodystrophie affecte-t-elle la qualité de vie ?
Elle peut réduire la qualité de vie en affectant l'estime de soi et les interactions sociales.
Qualité de vieEstime de soiLipodystrophie
#5
Les complications sont-elles réversibles ?
Certaines complications peuvent être gérées ou améliorées, mais pas toutes ne sont réversibles.
RéversibilitéComplicationsLipodystrophie
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les principaux facteurs incluent l'utilisation prolongée d'antirétroviraux et des antécédents familiaux.
Facteurs de risqueAntirétrovirauxAntécédents familiaux
#2
L'âge influence-t-il le risque de lipodystrophie ?
Oui, le risque augmente avec l'âge, surtout chez les personnes vivant avec le VIH.
ÂgeRisqueVIH
#3
Le sexe joue-t-il un rôle dans le risque ?
Oui, des études montrent que les hommes peuvent être plus à risque que les femmes.
SexeRisqueLipodystrophie
#4
Les habitudes alimentaires influencent-elles le risque ?
Oui, une alimentation déséquilibrée peut augmenter le risque de lipodystrophie.
Habitudes alimentairesRisqueLipodystrophie
#5
Le manque d'exercice est-il un facteur de risque ?
Oui, un mode de vie sédentaire peut contribuer au développement de la lipodystrophie.
ExerciceRisqueLipodystrophie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lipodystrophie associée au VIH : Questions médicales les plus fréquentes",
"headline": "Lipodystrophie associée au VIH : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lipodystrophie associée au VIH : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lipodystrophie associée au VIH"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Infections à VIH",
"url": "https://questionsmedicales.fr/mesh/D015658",
"about": {
"@type": "MedicalCondition",
"name": "Infections à VIH",
"code": {
"@type": "MedicalCode",
"code": "D015658",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.673.480"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lipodystrophie associée au VIH",
"alternateName": "HIV-Associated Lipodystrophy Syndrome",
"code": {
"@type": "MedicalCode",
"code": "D039682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David Araújo-Vilar",
"url": "https://questionsmedicales.fr/author/David%20Ara%C3%BAjo-Vilar",
"affiliation": {
"@type": "Organization",
"name": "UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine (Medicine Area), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)-IDIS, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain. david.araujo@usc.es."
}
},
{
"@type": "Person",
"name": "Ferruccio Santini",
"url": "https://questionsmedicales.fr/author/Ferruccio%20Santini",
"affiliation": {
"@type": "Organization",
"name": "Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Giovanni Ceccarini",
"url": "https://questionsmedicales.fr/author/Giovanni%20Ceccarini",
"affiliation": {
"@type": "Organization",
"name": "Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy. Electronic address: giovanni.ceccarini@unipi.it."
}
},
{
"@type": "Person",
"name": "None Shyamveer",
"url": "https://questionsmedicales.fr/author/None%20Shyamveer",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biology, National AIDS Research Institute, Pune 411026, India. Electronic address: shyamveerbharati0@gmail.com."
}
},
{
"@type": "Person",
"name": "Abhimanyu Garg",
"url": "https://questionsmedicales.fr/author/Abhimanyu%20Garg",
"affiliation": {
"@type": "Organization",
"name": "Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, and Center for Human Nutrition, UT Southwestern Medical Center, Dallas, Texas, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Imaging of Body Composition.",
"datePublished": "2024-10-15",
"url": "https://questionsmedicales.fr/article/39406222",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0044-1788887"
}
},
{
"@type": "ScholarlyArticle",
"name": "Artificial intelligence and body composition.",
"datePublished": "2023-02-26",
"url": "https://questionsmedicales.fr/article/36867973",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.dsx.2023.102732"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of Body Composition in CrossFit",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36078716",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph191711003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Associations of weight and body composition at birth with body composition and cardiometabolic markers in children aged 10 y: the Ethiopian infant anthropometry and body composition birth cohort study.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37328067",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajcnut.2023.06.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prenatal weight and regional body composition trajectories and neonatal body composition: The NICHD Foetal Growth Studies.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36605025",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ijpo.12994"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Déficits immunitaires",
"item": "https://questionsmedicales.fr/mesh/D007153"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections à VIH",
"item": "https://questionsmedicales.fr/mesh/D015658"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lipodystrophie associée au VIH",
"item": "https://questionsmedicales.fr/mesh/D039682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lipodystrophie associée au VIH - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lipodystrophie associée au VIH",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lipodystrophie associée au VIH",
"description": "Comment diagnostiquer la lipodystrophie associée au VIH ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une lipodystrophie ?\nLa lipodystrophie est-elle toujours liée au VIH ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D039682?mesh_terms=Body+Composition#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lipodystrophie associée au VIH",
"description": "Quels sont les symptômes courants de la lipodystrophie ?\nLa lipodystrophie provoque-t-elle des douleurs ?\nY a-t-il des symptômes psychologiques associés ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLa lipodystrophie affecte-t-elle le métabolisme ?",
"url": "https://questionsmedicales.fr/mesh/D039682?mesh_terms=Body+Composition#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lipodystrophie associée au VIH",
"description": "Peut-on prévenir la lipodystrophie associée au VIH ?\nQuel rôle joue l'éducation dans la prévention ?\nLes changements de mode de vie peuvent-ils prévenir la lipodystrophie ?\nLes dépistages réguliers sont-ils importants ?\nLes patients doivent-ils être informés des risques ?",
"url": "https://questionsmedicales.fr/mesh/D039682?mesh_terms=Body+Composition#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lipodystrophie associée au VIH",
"description": "Quels traitements sont disponibles pour la lipodystrophie ?\nLes médicaments peuvent-ils aider à la lipodystrophie ?\nLa chirurgie est-elle une option pour tous ?\nComment le mode de vie influence-t-il le traitement ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D039682?mesh_terms=Body+Composition#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lipodystrophie associée au VIH",
"description": "Quelles complications peuvent survenir avec la lipodystrophie ?\nLa lipodystrophie augmente-t-elle le risque cardiovasculaire ?\nY a-t-il des complications psychologiques ?\nComment la lipodystrophie affecte-t-elle la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D039682?mesh_terms=Body+Composition#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lipodystrophie associée au VIH",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de lipodystrophie ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes habitudes alimentaires influencent-elles le risque ?\nLe manque d'exercice est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D039682?mesh_terms=Body+Composition#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la lipodystrophie associée au VIH ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et l'évaluation de la répartition des graisses."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme l'IRM ou la tomodensitométrie peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une lipodystrophie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements visibles dans la répartition des graisses, comme l'accumulation abdominale."
}
},
{
"@type": "Question",
"name": "La lipodystrophie est-elle toujours liée au VIH ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle peut aussi être causée par d'autres facteurs, mais le VIH est un facteur majeur."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique des traitements antirétroviraux aide à établir un lien avec la lipodystrophie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la lipodystrophie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une redistribution des graisses, souvent avec un ventre proéminent."
}
},
{
"@type": "Question",
"name": "La lipodystrophie provoque-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle ne provoque généralement pas de douleurs, mais peut affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes d'image corporelle et de dépression peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gravité et le type de symptômes peuvent varier selon les individus."
}
},
{
"@type": "Question",
"name": "La lipodystrophie affecte-t-elle le métabolisme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des troubles métaboliques comme la résistance à l'insuline."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la lipodystrophie associée au VIH ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un suivi médical régulier et une gestion appropriée des traitements."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation dans la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les effets des traitements antirétroviraux aide à prévenir la lipodystrophie."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils prévenir la lipodystrophie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, adopter un mode de vie sain peut réduire le risque de lipodystrophie."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers permettent de détecter précocement les signes de lipodystrophie."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients sur les risques aide à une meilleure gestion de leur santé."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la lipodystrophie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des modifications du mode de vie, des médicaments et parfois la chirurgie."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à la lipodystrophie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent améliorer la répartition des graisses et le métabolisme."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle une option pour tous ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie est généralement réservée aux cas sévères et après évaluation médicale."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant l'exercice et une alimentation équilibrée, est crucial."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie, mais une gestion continue est souvent nécessaire pour de meilleurs résultats."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la lipodystrophie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles métaboliques, cardiovasculaires et psychologiques."
}
},
{
"@type": "Question",
"name": "La lipodystrophie augmente-t-elle le risque cardiovasculaire ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est associée à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications psychologiques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes d'anxiété et de dépression peuvent survenir en raison de l'image corporelle."
}
},
{
"@type": "Question",
"name": "Comment la lipodystrophie affecte-t-elle la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire la qualité de vie en affectant l'estime de soi et les interactions sociales."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées ou améliorées, mais pas toutes ne sont réversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'utilisation prolongée d'antirétroviraux et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de lipodystrophie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les personnes vivant avec le VIH."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que les hommes peuvent être plus à risque que les femmes."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de lipodystrophie."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire peut contribuer au développement de la lipodystrophie."
}
}
]
}
]
}
UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine (Medicine Area), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)-IDIS, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain. david.araujo@usc.es.
Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706, Santiago de Compostela, Spain. david.araujo@usc.es.
Publications dans "Lipodystrophie associée au VIH" :
Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy. Electronic address: giovanni.ceccarini@unipi.it.
Publications dans "Lipodystrophie associée au VIH" :
Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, and Center for Human Nutrition, UT Southwestern Medical Center, Dallas, Texas, USA.
Publications dans "Lipodystrophie associée au VIH" :
UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine (Medicine Area), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)-IDIS, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706, Santiago de Compostela, Spain.
Publications dans "Lipodystrophie associée au VIH" :
UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine (Medicine Area), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)-IDIS, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Publications dans "Lipodystrophie associée au VIH" :
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.
Endocrinology Department, Assistance Publique-Hôpitaux de Paris, Saint-Antoine Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Publications dans "Lipodystrophie associée au VIH" :
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.
Endocrinology Department, Assistance Publique-Hôpitaux de Paris, Saint-Antoine Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Genetics Department, Assistance Publique-Hôpitaux de Paris, La Pitié-Salpêtrière Hospital, Paris, France.
Publications dans "Lipodystrophie associée au VIH" :
Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, F-59000 Lille, France; University of Lille, F-59000 Lille, France; INSERM U1190, European Genomic Institute for Diabetes, F-59000 Lille, France.. Electronic address: mc-vantyghem@chru-lille.fr.
Publications dans "Lipodystrophie associée au VIH" :
UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine (Medicine Area), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)-IDIS, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Publications dans "Lipodystrophie associée au VIH" :
Laboratoire commun de Biologie et Génétique Moléculaires, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris 75012, France. Electronic address: isabelle.jeru@aphp.fr.
Publications dans "Lipodystrophie associée au VIH" :
Department of Medicine, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo's Clinical Translational Research Center, 875 Ellicott Street, Buffalo, NY 14203, USA. Electronic address: smahajan@buffalo.edu.
Publications dans "Lipodystrophie associée au VIH" :
Body composition is now recognized to have a major impact on health and disease. Imaging enables its analysis in an objective and quantitative way through diverse techniques such as dual-energy X-ray ...
Although obesity is associated with chronic disease, a large section of the population with high BMI does not have an increased risk of metabolic disease. Increased visceral adiposity and sarcopenia a...
We searched the following databases: Embase, Web of Science, and PubMed. There was a total of 354 search results. After removing duplicates, irrelevant studies, and reviews(a total of 303), 51 studies...
AI techniques have been studied for body composition analysis in the context of diabetes mellitus, hypertension, cancer and many specialized diseases. Imaging techniques employed for AI methods includ...
AI assisted measurement of body composition might assist in improved cardiovascular risk stratification when applied in the appropriate clinical context....
Although birth weight (BW) has been associated with later cardiovascular disease and type 2 diabetes, the role of birth fat mass (BFM) and birth fat-free mass (BFFM) on cardiometabolic health is uncle...
To examine associations of BW, BFM, and BFFM with later anthropometry, body composition, abdominal fat, and cardiometabolic markers....
Birth cohort data on standardized exposure variables (BW, BFM, and BFFM) and follow-up information at age 10 y on anthropometry, body composition, abdominal fat, and cardiometabolic markers were inclu...
Among 353 children, mean (SD) age was 9.8 (1.0) y, and 51.5% were boys. In the fully adjusted model, 1-SD higher BW and BFFM were associated with 0.81 cm (95% CI: 0.21, 1.41 cm) and 1.25 cm (95% CI: 0...
BW and BFFM rather than BFM are predictors of height and FFM index at 10 y. Children with higher BW and BFFM showed higher insulin concentrations and homeostasis model assessment of insulin resistance...
Gestational weight gain (GWG) and anthropometric trajectories may affect foetal programming and are potentially modifiable....
To assess concomitant patterns of change in weight, circumferences and adiposity across gestation as an integrated prenatal exposure, and determine how they relate to neonatal body composition....
Data are from a prospective cohort of singleton pregnancies (n = 2182) enrolled in United States perinatal centres, 2009-2013. Overall and by prepregnancy BMI group (overweight/obesity and healthy wei...
Six trajectory patterns reflecting co-occurring changes in weight and MUAC, SSF and TSF across pregnancy were identified overall and by body mass index (BMI) group. Among people with a healthy weight ...
Six integrated trajectory patterns of prenatal weight, subcutaneous adipose tissue and circumferences were observed that were minimally associated with neonatal body composition, suggesting a stronger...
The general perception is that menstrual cycle is a factor related to body weight and body composition fluctuations in women. The lack of a standardized methodology of the so far conducted studies has...
In the current study measurements of body weight, circumferences, skinfolds and body composition with bioelectrical impedance analysis were conducted twice per week in 42 women during their menstrual ...
Body weight was found to be statistically significantly higher during menstruation compared to the first week of the menstrual cycle by 0.450 kg, which could be attributed to a statistically significa...
An increase of approximately 0.5 kg was observed during women's menstrual cycle, mostly due to extracellular fluid retention at menstruation days. These findings could be taken into account to interpr...
This cross-sectional study used compositional data analysis (CoDA) to do the following: 1) analyze the relative associations between fat and lean tissues with cardiometabolic risk factors; and 2) esti...
A total of 397 adults with overweight or obesity were studied. Body composition consisted of visceral fat, abdominal subcutaneous fat, peripheral subcutaneous fat, other fat depots, skeletal muscle, a...
Visceral fat mass, relative to the mass of the remaining tissues, was significantly associated with the metabolic syndrome score and five of eight remaining risk factors (p < 0.05). The relative contr...
These CoDA findings reinforce that excess visceral fat contributes to less-favorable cardiometabolic risk factors....
The proportion of obese or overweight patients in COPD patients is increasing. Although BMI, WC and other easy to measure indicators have been proven to be related to the risk of COPD, they cannot acc...
Obesity is the most extended metabolic alteration worldwide increasing the risk for the development of cardiometabolic alterations such as type 2 diabetes, hypertension, and dyslipidemia. Body mass in...
Metabolism encompasses the entire array of chemical reactions continuously occurring within the body that sustain life and maintain normal physiological functions [...]....